EMA: Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD)

This Guideline is intended to provide guidance on the evaluation of new medicinal products in ADHD with focus on the childhood onset. It is the first guideline written in psychiatry to address a (child) psychiatric disorder from this perspective, and it should be read in conjunction with other EMA and ICH guidelines, which may apply to similar conditions and patient populations.